SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study

Walker, WT; de Whalley, P; Andrews, N; Oeser, C; Casey, M; Michaelis, L; Hoschler, K; Harrill, C; Moulsdale, P; Thompson, B; et al. Walker, WT; de Whalley, P; Andrews, N; Oeser, C; Casey, M; Michaelis, L; Hoschler, K; Harrill, C; Moulsdale, P; Thompson, B; Jones, C; Chalk, J; Kerridge, S; John, TM; Okike, I; Ladhani, S; Tomlinson, R; Heath, PT; Miller, E; Faust, SN; Snape, MD; Finn, A; Pollard, AJ (2012) H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study. CLINICAL INFECTIOUS DISEASES, 54 (5). 661 - 669. ISSN 1058-4838 https://doi.org/10.1093/cid/cir905
SGUL Authors: Heath, Paul Trafford

[img]
Preview
["document_typename_cannot open `/data/SGUL/sgul/eprints3/archives/sgul/documents/disk0/00/10/71/43/01/Clin' (No such file or directory) cannot open `Infect' (No such file or directory) cannot open `Dis.-2012-Walker-661-9.pdf' (No such file or directory)" not defined] Published Version
Available under License St George's repository terms & conditions.

Download (391kB) | Preview

Abstract

Background. We investigated antibody persistence in children 1 year after 2 doses of either an AS03B-adjuvanted split-virion or nonadjuvanted whole-virion monovalent pandemic influenza vaccine and assessed the immunogenicity and reactogenicity of a subsequent dose of trivalent influenza vaccine (TIV). Methods. Children previously immunized at age 6 months to 12 years in the original study were invited to participate. After a blood sample was obtained to assess persistence of antibody against swine influenza A/H1N1(2009) pandemic influenza, children received 1 dose of 2010/2011 TIV, reactogenicity data were collected for 7 days, and another blood sample was obtained 21 days after vaccination. Results. Of 323 children recruited, 302 received TIV. Antibody persistence (defined as microneutralization [MN] titer ≥1:40) 1 year after initial vaccination was significantly higher in the AS03B-adjuvanted compared with the whole-virion vaccine group, 100% (95% confidence interval [CI], 94.1%–100%) vs 32.4% (95% CI, 21.5%–44.8%) in children immunized <3 years old and 96.9% (95% CI, 91.3%–99.4%) vs 65.9% (95% CI, 55.3%–75.5%) in those 3–12 years old at immunization, respectively (P < .001 for both groups). All children receiving TIV had post-vaccination MN titers ≥1:40. Although TIV was well tolerated in all groups, reactogenicity in children <5 years old was slightly greater in those who originally received AS03B-adjuvanted vaccine. Conclusions. This study provides serological evidence that 2 doses of AS03B-adjuvanted pandemic influenza vaccine may be sufficient to maintain protection across 2 influenza seasons. Administration of TIV to children who previously received 2 doses of either pandemic influenza vaccine is safe and is immunogenic for the H1N1 strain.

Item Type: Article
Additional Information: © The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
Keywords: Adjuvants, Immunologic, Antibodies, Viral, Follow-Up Studies, Hemagglutination Inhibition Tests, Humans, Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human, Neutralization Tests, Virion, Science & Technology, Life Sciences & Biomedicine, Immunology, Infectious Diseases, Microbiology, IMMUNOLOGY, INFECTIOUS DISEASES, MICROBIOLOGY, SPLIT VIRION, AGE, INFECTION, CHILDREN, VIRUS, SERUM, Microbiology, 06 Biological Sciences, 11 Medical And Health Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: CLINICAL INFECTIOUS DISEASES
ISSN: 1058-4838
Related URLs:
Dates:
DateEvent
1 March 2012Published
Web of Science ID: WOS:000300228300013
URI: https://openaccess.sgul.ac.uk/id/eprint/107143
Publisher's version: https://doi.org/10.1093/cid/cir905

Actions (login required)

Edit Item Edit Item